Internacional (Marketwired, 08 de Agosto de 2013) Kerecis Limited, the emerging tissue-regeneration company, today announced the formation of a corporate scientific advisory board consisting of recognized experts in wound care and surgical implants.The board will review the company's progress in research and clinical development, and help the company's management evaluate new scientific perspectives. The board will be chaired by Dr. Robert S. Kirsner of the University of Miami.
The board members are Dr. Robert S. Kirsner (University of Miami), Dr. David Margolis (University of Pennsylvania), Dr. Magnus S. Agren (University of Copenhagen), and Madeleine Flanagan (University of Hertfordshire, UK).
Robert S Kirsner, M.D., PhD, is a tenured professor and vice chairman in the Department of Dermatology and Cutaneous Surgery at the University of Miami Miller School of Medicine. He is a past president of the Florida Society of Dermatology and Dermatologic Surgery (FSDDS), former board member of the Wound Healing Society (WHS), and a founding member and past president of the Association for the Advancement of Wound Care (AAWC). Dr. Kirsner co-directs the largest multi-disciplinary wound-care meeting in the United States, the Symposium for Advanced Wound Care (SAWC). The co-editor of the comprehensive book, "Wound Healing," he has authored more than 350 peer-reviewed articles including articles in the "New England Journal of Medicine," "Lancet" and "Annals of Internal Medicine."
David Margolis, M.D., PhD, is a tenured professor of dermatology and epidemiology at the University of Pennsylvania. A former board member of the Wound Healing Society, he is currently on the board of the Society for Investigative Dermatology. He conducts epidemiologic and translation research on chronic wounds, atopic dermatitis, and acne. His research has been sponsored by the NIH, AHRQ, FDA, not-for-profit foundations, and industry. He has more than 200 peer-reviewed articles including those in general medical journals like the "New England Journal of Medicine," "Journal of the American Medical Association," "British Medical Journal" and "Lancet," as well as in more wound-specific journals like "Diabetes Care," "Journal of Investigative Dermatology" and "Wound Repair and Regeneration."
Magnus S. Agren, Doctor of Medical Science, is an adjunct professor of human pathology at the Faculty of Health and Medical Sciences, University of Copenhagen, Denmark. Dr. Agren, who has invented three wound-care products, has held positions at the wound care companies Mölnlycke Health Care and Coloplast. The author of more than 100 peer-reviewed articles on biomedicine, he is an editorial board member of the "Journal of Wound Care, Wound Repair and Regeneration," "The Open Dermatology Journal" and "The Open Colorectal Cancer Journal." Dr. Agren is also on the board of the European Tissue Repair Society.
Madeleine Flanagan, RN, MSc (Distinction), is a principal lecturer in skin integrity and dermatology in Postgraduate Medicine, School of Life and Medical Sciences, University of Hertfordshire (UK). She has been a skin specialist for more than 25 years with a particular interest in chronic wounds. Flanagan was a founding member and past chairperson of the Wound Healing Society (UK). She is the program director for the MSc Skin Integrity Skills and the MSc Dermatology Skills & Treatment at the University of Hertfordshire Postgraduate Medical School. Flanagan is the editor of the recently published book "Wound Healing and Skin Integrity: Principles and Practice" and author of more than 100 peer-reviewed articles on chronic wound management.
Comment:
Gudmundur Fertram Sigurjonsson, Executive Chairman, Kerecis Limited:
"We are delighted to have access to the expertise of such respected experts. We look forward to their assistance and insights, as we continue our research and clinical development."
About Kerecis
Kerecis (http://www.kerecis.com) is a development and manufacturing company that produces a novel, patent-pending, tissue-regeneration material derived from fish skin to accelerate the healing of wounds and tissue reconstruction. The Kerecis material addresses the large, so-far-unmet need of the double-digit-growth biologics segment of the chronic-wounds, hernia-repair and dermatology markets.
Development programs involve the creation of regenerative technologies for repairing damaged tissue in vivo, as well as growing the tissues and organs in vitro and implanting them into the patient at a later stage. The Kerecis material offers advantages over existing human- and porcine-derived products, including improved manufacturing economics and a lower risk of disease transfer. Since it is derived from fish, the material is both kosher and halal compatible, eliminating cultural and religious constraints to usage, with equivalent or better clinical performance than alternative approaches. For more information, e-mail: info@kerecis.com or call 703-879-6535 (U.S.) or +354-8494960 (Iceland).
Contact Information
For further information, contact:
G. Fertram Sigurjonsson
Executive Chairman
Kerecis Limited
Phone (Iceland) +354-8494960
(U.S.) 703-879-6535
E-mail: Email Contact
FUENTE: MARKETWIRED
